Diabetes Care, Vol 23, Issue 4 518-523, Copyright © 2000 by American Diabetes Association

ARTICLES

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

DR Owens, SD Luzio, I Ismail and T Bayer
Diabetes Research Unit, University of Wales College of Medicine, South Glamorgan, U.K. owensdr@cf.ac.uk

OBJECTIVE: To examine the dose-related pharmacodynamics and pharmacokinetics of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 16 Caucasian men with type 2 diabetes participated in two placebo-controlled double-blind randomized cross-over studies. Patients were randomized to receive a single oral dose of repaglinide (0.5, 1.0, and 2.0 mg in study 1 and 4.0 mg in study 2) or placebo (both studies) administered 15 min before the first of two sequential identical standard meals (breakfast and lunch) that were 4 h apart. During each of the study days, which were 1 week apart, blood samples were taken at frequent intervals over a period of approximately 8 h for measurement of plasma glucose, insulin, C-peptide, and repaglinide concentrations. RESULTS: During the first meal period (0-240 min), administration of repaglinide reduced significantly the area under the curve (AUC) for glucose concentration and significantly increased the AUC for insulin levels, C-peptide levels, and the insulin secretion rate. These results, compared with those of administering placebo, were dose dependent and log linear. The effect of repaglinide administration on insulin secretion was most pronounced in the early prandial period. Within 30 min, it caused a relative increase in insulin secretion of up to 150%. During the second meal period (240-480 min), there was no difference between repaglinide and placebo administration in the AUC for glucose concentration, C-peptide concentration, and the estimated insulin secretion rate. CONCLUSIONS: A single dose of repaglinide (0.5-4.0 mg) before breakfast improves insulin secretion and reduces prandial hyperglycemia dose-dependently Administration of repaglinide had no effect on insulin secretion with the second meal, which was consumed 4 h after breakfast.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Scarsi, M. Podvinec, A. Roth, H. Hug, S. Kersten, H. Albrecht, T. Schwede, U. A. Meyer, and C. Rucker Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor {gamma} Activity: A Combined Virtual Screening and Biological Assay Approach Mol. Pharmacol., February 1, 2007; 71(2): 398 - 406. [Abstract] [Full Text] [PDF]

				L. S. Cozma, S. D. Luzio, G. J. Dunseath, P. M. Underwood, and D. R. Owens {beta}-Cell Response During a Meal Test: A comparative study of incremental doses of repaglinide in type 2 diabetic patients Diabetes Care, May 1, 2005; 28(5): 1001 - 1007. [Abstract] [Full Text] [PDF]

				A. Ceriello, M. Hanefeld, L. Leiter, L. Monnier, A. Moses, D. Owens, N. Tajima, J. Tuomilehto, and for the International Prandial Glucose Regulation Postprandial Glucose Regulation and Diabetic Complications Arch Intern Med, October 25, 2004; 164(19): 2090 - 2095. [Abstract] [Full Text] [PDF]

				M. S. Thomsen, D. Chassard, E. Evene, K. K. Nielsen, and M. Jorgensen Pharmacokinetics of Repaglinide in Healthy Caucasian and Japanese Subjects J. Clin. Pharmacol., January 1, 2003; 43(1): 23 - 28. [Abstract] [Full Text]

				L. S. Cozma, S. D. Luzio, G. J. Dunseath, K. W. Langendorg, T. Pieber, and D. R. Owens Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal Diabetes Care, August 1, 2002; 25(8): 1271 - 1276. [Abstract] [Full Text] [PDF]